These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1824899)

  • 1. Effect of the HLA-DRw6 antigen in liver transplantation.
    Saito S; Stratta RJ; Grazi GL; Castaldo P; Langnas AN; Wood RP; Shaw BW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1430-1. PubMed ID: 1824899
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 3. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 4. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
    Ippoliti G; Fronterrè A
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.
    Renard TH; Andrews WS; Foster ME
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1473-6. PubMed ID: 1846468
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolonged and repeated courses of OKT3 after liver transplantation.
    Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
    Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
    [No Abstract]   [Full Text] [Related]  

  • 7. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

  • 8. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 9. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
    Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
    Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
    Chen M; Wade J; Levy GA; Greig PD
    Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
    [No Abstract]   [Full Text] [Related]  

  • 13. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
    Hirsch R; Bluestone JA; Bare CV; Gress RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 15. HLA-DR1, -DR5, and -DR8 antigen disparities are associated with acute steroid-resistant rejection and poor kidney graft survival.
    Salmela K; von Willebrand E; Kyllönen L; Koskimies S; Isoniemi H; Eklund B; Höckerstedt K; Ahonen J
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1272-3. PubMed ID: 1899160
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with OKT3 after orthotopic liver transplantation.
    Stratta R; Shaefer M; Bradshaw K; Wood R; Langnas A; Zetterman R; Donovan J; Sorrell M; Markin R; Shaw BW
    Transplant Proc; 1991 Jun; 23(3):1970. PubMed ID: 1829556
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 18. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 19. [The immunobiology of transplant rejection and its pharmacological modification].
    Köhler H; Zanker B; Strom TB
    Dtsch Med Wochenschr; 1991 Feb; 116(7):264-9. PubMed ID: 1825196
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
    Langrehr JM; Neuhaus PJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.